BR112016026811A2 - formulação de anticorpo - Google Patents

formulação de anticorpo

Info

Publication number
BR112016026811A2
BR112016026811A2 BR112016026811A BR112016026811A BR112016026811A2 BR 112016026811 A2 BR112016026811 A2 BR 112016026811A2 BR 112016026811 A BR112016026811 A BR 112016026811A BR 112016026811 A BR112016026811 A BR 112016026811A BR 112016026811 A2 BR112016026811 A2 BR 112016026811A2
Authority
BR
Brazil
Prior art keywords
antibody formulation
antigen binding
binding protein
monoclonal antibody
pharmaceutically active
Prior art date
Application number
BR112016026811A
Other languages
English (en)
Portuguese (pt)
Inventor
BLAKE-HASKINS Angela
M Dunleavy Donna
H Crotts George
O'berry Kristen
PURI Manasi
D Perkins Melissa
MARSHALL Tristan
Original Assignee
Glaxosmithkline Intellectual Property Man Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property Man Limited filed Critical Glaxosmithkline Intellectual Property Man Limited
Publication of BR112016026811A2 publication Critical patent/BR112016026811A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
BR112016026811A 2014-05-16 2015-05-15 formulação de anticorpo BR112016026811A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461994427P 2014-05-16 2014-05-16
US201462093734P 2014-12-18 2014-12-18
US201462095181P 2014-12-22 2014-12-22
PCT/IB2015/053602 WO2015173782A1 (en) 2014-05-16 2015-05-15 Antibody formulation

Publications (1)

Publication Number Publication Date
BR112016026811A2 true BR112016026811A2 (pt) 2017-12-12

Family

ID=53200250

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016026811A BR112016026811A2 (pt) 2014-05-16 2015-05-15 formulação de anticorpo

Country Status (16)

Country Link
US (5) US10556009B2 (https=)
EP (3) EP3719038A1 (https=)
JP (2) JP6707528B2 (https=)
KR (2) KR102501602B1 (https=)
CN (1) CN106661111A (https=)
AU (1) AU2015260758B2 (https=)
BR (1) BR112016026811A2 (https=)
CA (1) CA2949212C (https=)
DK (1) DK3143047T3 (https=)
ES (1) ES2927990T3 (https=)
IL (1) IL248802B (https=)
MX (1) MX381232B (https=)
MY (1) MY185802A (https=)
SG (1) SG11201609622PA (https=)
TW (1) TWI694836B (https=)
WO (1) WO2015173782A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI694836B (zh) 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
WO2016065181A1 (en) 2014-10-23 2016-04-28 Amgen Inc. Reducing viscosity of pharmaceutical formulations
US20190175683A1 (en) * 2016-08-05 2019-06-13 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor
IL317989A (en) 2016-08-17 2025-02-01 Compugen Ltd Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
MX2019012255A (es) * 2017-04-11 2019-12-05 Kiniksa Pharmaceuticals Ltd Formulacion estable de anticuerpo contra el receptor de oncostatina m (osmr).
CN110769848A (zh) * 2017-05-16 2020-02-07 瑞士奥克特珐玛公司 C1-酯酶抑制剂制剂
WO2019201904A1 (en) * 2018-04-16 2019-10-24 Merck Patent Gmbh Viscosity reduction of highly concentrated protein formulations
KR20210096640A (ko) * 2018-11-29 2021-08-05 하버 바이오메드 테라푸틱스 리미티드 항-pd-l1 항체 제제
AU2020251627A1 (en) * 2019-03-29 2021-11-11 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing antibody against IL-5 and use thereof
EP4003417A2 (en) * 2019-07-29 2022-06-01 Compugen Ltd. Anti-pvrig antibodies formulations and uses thereof
KR20220093347A (ko) * 2019-11-06 2022-07-05 노파르티스 아게 쇼그렌 증후군의 치료
KR20230006824A (ko) 2020-04-24 2023-01-11 킹스칼리지런던 Ige 항체를 포함하는 조성물
CN113546252A (zh) * 2020-04-24 2021-10-26 上海君实生物医药科技股份有限公司 抗pcsk9抗体的药物递送装置
GB202006093D0 (en) 2020-04-24 2020-06-10 King S College London Composition
US20230220092A1 (en) * 2020-06-12 2023-07-13 GlaxSmithKline Intellectual Property Management Limited Anti-Blys Antibody for Treating Proteinuric Kidney Disease
WO2022106460A2 (en) 2020-11-18 2022-05-27 Astrazeneca Ab Steroid sparing
US20240301031A1 (en) 2021-03-31 2024-09-12 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Truncated taci polypeptide and fusion protein and use thereof
WO2022223028A1 (zh) * 2021-04-23 2022-10-27 上海君实生物医药科技股份有限公司 抗BLyS抗体、其药物组合物及其用途
BR112023024657A2 (pt) * 2021-06-17 2024-02-20 Glaxosmithkline Intellectual Property Ltd Anticorpos anti-baff para uso em um método de tratamento de covid longo e/ou sequelas agudas pós-infecção por sars-cov2 (pasc)
KR20240038773A (ko) 2021-07-27 2024-03-25 아스트라제네카 아베 루푸스의 치료
AU2023274641A1 (en) * 2022-05-23 2024-09-19 Regenecore Biotech Co., Ltd Stable antibody preparation
WO2024027793A1 (en) * 2022-08-05 2024-02-08 I-Mab Biopharma (Hangzhou) Co., Ltd. Bispecific antibodies targeting ifnar1 and blys
AU2024239150A1 (en) 2023-03-21 2025-10-02 Biograph 55, Inc. Cd19/cd38 multispecific antibodies
CN118255895B (zh) * 2024-04-30 2024-10-29 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 抗BAFF和hIL21双特异性抗体及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
PT1419179E (pt) 2001-08-10 2010-03-16 Univ Aberdeen Domínios de ligação de antigenes
AR035119A1 (es) * 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
IL161677A0 (en) * 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
CA2542777C (en) 2003-10-23 2016-02-02 Chiron Corporation Stabilised compositions
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
WO2007142667A2 (en) * 2005-10-13 2007-12-13 Human Genome Sciences, Inc. Treatment of patients with autoantibody positive disease
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
RU2012153786A (ru) 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
WO2011160086A2 (en) * 2010-06-18 2011-12-22 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to treat asthma and other allergic and inflammatory conditions of the respiratory system
WO2012076670A2 (en) * 2010-12-10 2012-06-14 Novartis Ag Antibody formulation
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
WO2013012022A1 (ja) 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
CN104768578A (zh) 2012-10-25 2015-07-08 米迪缪尼有限公司 稳定的低粘度抗体配制品
BR112015017619A2 (pt) * 2013-01-24 2017-11-21 Glaxosmithkline Ip Dev Ltd formulação líquida, uso de uma formulação, e, kit
TWI694836B (zh) 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
US9762377B2 (en) 2015-09-29 2017-09-12 Cable Television Laboratories, Inc. Hybrid full duplex communications in a radio frequency cable network

Also Published As

Publication number Publication date
EP3719038A1 (en) 2020-10-07
TWI694836B (zh) 2020-06-01
AU2015260758A1 (en) 2016-11-24
WO2015173782A1 (en) 2015-11-19
JP7277681B2 (ja) 2023-05-19
RU2016149151A3 (https=) 2019-03-12
US20220175922A1 (en) 2022-06-09
RU2743681C2 (ru) 2021-02-24
ES2927990T3 (es) 2022-11-14
US10556009B2 (en) 2020-02-11
KR20170005099A (ko) 2017-01-11
US12296007B2 (en) 2025-05-13
US11179463B2 (en) 2021-11-23
CA2949212C (en) 2023-12-19
MX381232B (es) 2025-03-12
AU2015260758B2 (en) 2017-11-02
KR20220148329A (ko) 2022-11-04
US20170095555A1 (en) 2017-04-06
US20250249095A1 (en) 2025-08-07
DK3143047T3 (da) 2022-10-17
JP6707528B2 (ja) 2020-06-10
JP2017515909A (ja) 2017-06-15
TW201601756A (zh) 2016-01-16
EP3715371A1 (en) 2020-09-30
EP3143047A1 (en) 2017-03-22
IL248802A0 (en) 2017-01-31
EP3143047B8 (en) 2022-09-07
KR102501602B1 (ko) 2023-02-17
SG11201609622PA (en) 2016-12-29
CN106661111A (zh) 2017-05-10
JP2020114819A (ja) 2020-07-30
US20180289804A1 (en) 2018-10-11
MX2016015006A (es) 2017-09-28
US20200222535A1 (en) 2020-07-16
MY185802A (en) 2021-06-09
EP3143047B1 (en) 2022-07-20
IL248802B (en) 2020-02-27
RU2016149151A (ru) 2018-06-20
CA2949212A1 (en) 2015-11-19

Similar Documents

Publication Publication Date Title
BR112016026811A2 (pt) formulação de anticorpo
CL2017001610A1 (es) Anticuerpos humanos para hemagglutinina de influenza
MX395147B (es) Formulación de anticuerpo anti-cgrp.
BR112018005349A2 (pt) preparação farmacêutica de anticorpo anti-pd-1 estável e sua aplicação em medicamentos
MX2022014781A (es) Formulaciones de anticuerpos anti-pdl1.
EP3618871A4 (en) FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
CO2019007823A2 (es) Anticuerpo anti-cd3 y moléculas que comprenden el anticuerpo
CL2017001115A1 (es) Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf.
IL275798A (en) Methods for antibody drug conjugation, purification and formulation
MX2017010400A (es) Formulacion liquida estable para anticuerpos monoclonales.
CO2019004186A2 (es) Inmunoglobulinas y usos de estas
CY1120937T1 (el) Φαρμακευτικη μορφοποιηση αντισωματος anti-tnf-αλφα
MX2018015272A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
BR112018003984A2 (pt) anticorpos
MX2018015268A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
BR112014021325A2 (pt) Formulação farmacêutica líquida e formulação liofilizada
MX387450B (es) Regimenes de dosificacion para compuestos de la clase de las equinocandinas.
MX2018015274A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
BR112019001233A2 (pt) formulação farmacêutica e uso da mesma
EA201790239A1 (ru) Молекула-носитель для антигенов
BR112017004393A2 (pt) formulações de anticorpo
EA201591579A1 (ru) Способы лечения болезни крона при помощи анти-il-23 антитела
WO2018119351A8 (en) Anti-sez6l2 antibodies and antibody drug conjugates
DK3672631T5 (da) Farmaceutiske sammensætninger indeholdende anti-beta-amyloid-antistoffer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: GLAXOSMITHKLINE INTELLECTUAL PROPERTY MANAGEMENT LIMITED (GB) ; GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25G Requested change of headquarter approved

Owner name: GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) ; GLAXOSMITHKLINE INTELLECTUAL PROPERTY MANAGEMENT LIMITED (GB)

B25G Requested change of headquarter approved

Owner name: GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) ; GLAXOSMITHKLINE INTELLECTUAL PROPERTY MANAGEMENT LIMITED (GB)